Pharma News

AbbVie announced the launch of PRODUODOPA® (foslevodopa/foscarbidopa) in the European Union for the treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia (excessive movement) or dyskinesia (involuntary movement), and when available combinations of Parkinson's medicinal products have not given satisfactory results.

Dr. Mansukh Mandaviya, Union Minister of Health and Family Welfare inaugurated the Central Drugs Standard Control Organization (CDSCO) Sub Zonal office and Central Drug Testing Laboratory (CDTL) in Indore, Madhya Pradesh today.

With the launch of ICD 11, Traditional Medicine Module 2 by the World Health Organization today, preparations have started for its implementation. The data and terminology relating to diseases based on Ayurveda, Siddha and Unani Medicine have been included in the WHO ICD-11 classification. With this effort, the terminology defining diseases in Ayurveda, Unani and Siddha medicine has been indexed as a code and included in the WHO Disease Classification Series ICD-11.

GSK plc and Aiolos Bio, Inc announced that they have entered into an agreement under which GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with certain respiratory and inflammatory conditions, for a 1 billion USD upfront payment and up to 400 million USD in certain success-based regulatory milestone payments.

Astellas Pharma Inc. announced the U.S. Food and Drug Administration (FDA) issued a complete response letter on January 4, 2024, regarding the Biologics License Application (BLA) for zolbetuximab, an investigational agent for the treatment of patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive.

Pfizer Inc announced that the European Commission (EC) has approved TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. With this approval, TALZENNA is now the first and only PARP inhibitor licensed in the European Union for use with XTANDI for patients with mCRPC, with or without gene mutations.

Mayo Clinic Platform, a collaborative ecosystem for healthcare innovation, and Techcyte, a world leader in AI-based digital pathology, are working together to transform the global practice of pathology through the creation of a digital pathology platform.

A new study published in the journal Diabetes demonstrates that a glucagon-like peptide-1 receptor (GLP-1R) agonist, a member of a class of medication used to treat Type 2 diabetes and obesity, can lead to a rapid improvement in insulin sensitivity.

Researchers at the University of Michigan Health Rogel Cancer Center have identified a mechanism that causes severe gastrointestinal problems with immune-based cancer treatment.

They also found a way to deliver immunotherapy’s cancer-killing impact without the unwelcome side effect.